Report top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trials

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced: 28 Oct 2021
Due: 31 Dec 2021
Checked: 2 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2021-10-28
FilingSEC filing index
Deadline as statedin the Fourth Quarter of 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-ALDX-003446
Cite as https://keptindex.org/c/KI-C-2021-ALDX-003446/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not report top-line results for the TRANQUILITY-2 trial by the end of 2021, subsequently pushing the expected reporting date to mid-2022 in filings dated March 2022.

A
Aldeyra Therapeutics, Inc. 8-K filed 2022-03-17 Regulatory filing · published 17 Mar 2022 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 51f6c9bf3031
“Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected Mid-2022” ✓ confirmed on the page

Market reaction: the shares moved +12.3% against the S&P 500 over the three sessions around the disclosure (16 Mar 2022 to 21 Mar 2022). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1277 days
3 versions

Version 1 · original · stated 28 Oct 2021

Deadline 31 Dec 2021 (“in the Fourth Quarter of 2021”) · wording expected
Version 2 · stated 18 May 2022

Deadline 30 Jun 2022 (“the Second Quarter of 2022”) · wording expected

“TRANQUILITY-2 Top-Line Results Expected in the Second Quarter of 2022”
Source for this version
Version 3 · stated 3 Apr 2025

Deadline 30 Jun 2025 (“Q2 2025”) · wording expected

“Top-line results from dry eye disease field and chamber clinical trials are expected in Q2 2025.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trial results
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Partly met”.
Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.